prof-georgina-long

Professor Georgina Long AO

BSc PhD MBBS FRACP FAHMS AAHMS FAA FASCO

Medical Director

Professor Georgina Long AO, BSc (Hons1, UM) PhD MBBS (Hons) FRACP FAHMS AAHMS FAA FASCO, is Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on immuno-oncology and targeted therapies in melanoma. She is principal investigator on phase I, II and III clinical trials in (neo)adjuvant and metastatic melanoma, including trials in patients with active brain metastases. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance.

In recognition of her ground-breaking research and work, Professor Long was named 2024 Australian of the Year and was awarded prestigious Fellowships with the American Society for Clinical Oncology (2025), the Australian Academy of Science (2024) and the Australian Academy of Health and Medical Sciences (2017), the latter awarding her the Outstanding Female Research Medal (2021). Professor Long was appointed as an Officer of the Order of Australia (2020) and has received numerous awards, including Fulbright U.S. Mission Australia Award for Leadership Excellence (2024), Estela Medrano Melanoma Award (2024), ESMO Women for Oncology Award (2023), Sydney Local Health District/Sydney Research 2022 Research Excellence Award (2022) the prestigious Ramaciotti Medal for Biomedical Research (2021), Vice Chancellor’s Award for Excellence Award for Outstanding Research (2021), University of Sydney (2021), Research Australia GSK Research Excellence Award (2018) and the Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research (2016). She has a number of CINSW Premiers Awards, including: the Outstanding Cancer Researcher (2018), the Excellence in Translational Cancer Research Award (2017), the Wildfire Award for the most highly-cited, original, peer-reviewed article published (2011, 2014, 2016, 2017, 2018, 2019 & 2020), and in 2013 she was named the Outstanding Cancer Research Fellow. She is a Clarivate highly-cited Researcher from 2017, with an H index of 155.

Professor Long is the author of over 610 peer-reviewed publications in clinical and translational research in melanoma, including the New England Journal of Medicine, Lancet, Lancet Oncology, Science, Nature, Nature Medicine, Journal of Clinical Oncology and Cancer Discovery. Professor Long has presented her work at international conferences and meetings on more than 300 occasions. She was President for the prestigious international Society for Melanoma Research (President 2018-2020), is a member and Chair of the ASCO (2015-2017) and ESMO (2017-2020 & 2026 – 2029) Scientific Committee for Melanoma/Skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, and is member of both the ASCO Plenary Series and ASCO AGM Education committees (2021-2024), Scientific Co-Chair for ESMO Asia (2024) and EADO (2026), she is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.

 Professor Long was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and their binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Professor Long became a Fellow of the Australasian College of Physicians in January 2008, specialising in medical oncology.

Please follow Georgina on social:
Twitter: @ProfGLongMIA
Instagram: @profglong

Contact details 

For all media enquiries, please email media@melanoma.org.au

To make a medical appointment to see Prof Georgina Long AO, or for any clinical concerns, please email smo_reception@melanoma.org.au

To contact Professor Georgina Long AO on all other matters, please email her Executive Assistant, Bruna Barrios, at ealong@melanoma.org.au

Prof Long Recent News

Prof Long Recent Publications

Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

2025-11-10T13:57:52+11:00November 10th, 2025|

van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Bagge RO, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI, International Neoadjuvant Melanoma C. Annals of Surgical Oncology, (Apr 15 2022), doi:10.1245/s10434-022-11622-0. TOP 10%

|

Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study.

2025-10-28T10:58:52+11:00June 9th, 2025|

Mandalà M, Amaral T, Rutkowski P, Sergi MC, Rasch M-L, Benannoune N, Serra P, Vitale MG, Giannarelli D, Arance AM, Couselo EM, Neyns B, Dirven I, Tucci M, Guida M, Spagnolo F, Rossi E, Queirolo P, Quaglino P, Depenni R, Placzke J, Giacomo AMD, Del Vecchio M, Indini A, Silva IPd, Menzies AM, Hong A, Lorigan P, Long GV, Robert C, Ascierto PA. European Journal of Cancer, 225(Jul 25 2025): 115567, doi:https://doi.org/10.1016/j.ejca.2025.115567.

|

Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders.

2025-06-19T16:02:45+10:00June 4th, 2025|

Fletcher K, Machaalani M, El Hajj Chehade R, Nassar AH, Nawfal R, Manos M, Menzies AM, Aboubakar-Nana F, Hassel JC, Pinato DJ, Johnson A, Olsson-Brown AC, Carlino MS, Malgeri A, Cortellini A, Singh A, Parikh K, Kim SY, Naqash AR, Long GV, Challa P, Choueiri TK, Sharon E, Shah S, Johnson DB. JAMA Network Open, 8, no. 6, (Jun 04 2025): e2513727-e27, doi:10.1001/jamanetworkopen.2025.13727.

|

Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update.

2025-06-19T16:16:49+10:00June 3rd, 2025|

Lipson EJ, Stephen Hodi F, Tawbi H, Schadendorf D, Ascierto PA, Matamala L, Gutierrez EC, Rutkowski P, Gogas HJ, Lao CD, Menezes JJD, Dalle S, Arance A, Gaudy-Marqueste C, Chen B, Jackson W, Mukherjee S, Dolfi S, Long GV. European Journal of Cancer, (Jun 03 2025): 115547, doi:https://doi.org/10.1016/j.ejca.2025.115547.

|

Federated deep learning enables cancer subtyping by proteomics.

2025-06-19T15:25:25+10:00May 2nd, 2025|

Cai* Z, Boys* E, Noor* Z, Aref* A, Xavier D, Lucas N, Williams S, Koh J, Poulos R, Wu Y, Dausmann M, MacKenzie K, Aguilar A, Niell C, Barranco M, Basik M, Bowman E, Clifton-Bligh R, Connolly E, Cooper W, Dalal B, De Fazio A, Filipits M, Flynn P, Graham JD, George J, Gill A, Gnant M, Habib R, Harris C, Harvey K, Horvath L, Jackson C, Kohonen-Corish M, Lim E, Long GV, Lord R, Mann GJ, McCaughan G, Morgan L, Murphy L, Nagrial A, Panizza B, Samra J, Scolyer RA, Ioannis Souglakos I, Swarbrick A, Thomas D, Hains* P, Balleine* R, Robinson* P, Zhong* Q, Reddel* R. Cancer Discovery, (Accepted May 02 2025). TOP 10%

|

Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial.

2025-05-29T10:48:41+10:00April 15th, 2025|

Syeda MM, Long GV, Garrett J, Atkinson V, Santinami M, Schadendorf D, Hauschild A, Millward M, Mandala M, Chiarion-Sileni V, Smylie M, Manikhas GM, Dummer R, Wiggins JM, Ali S, Adnaik SB, Tan M, Dajee M, Polsky D. The Lancet Oncology, (Apr 15 2025), doi:10.1016/S1470-2045(25)00139-1.

|

Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort.

2025-05-29T09:54:07+10:00April 14th, 2025|

Braden J, Potter A, Rawson RV, Adegoke NA, Lo SN, Conway JW, Menzies AM, Carlino MS, Au-Yeung G, Saw RPM, Spillane AJ, Shannon KF, Pennington TE, Ch’ng S, Gyorki DE, Howle JR, Wilmott JS, Scolyer RA, Long GV, Pires da Silva I. Modern Pathology, (Apr 14 2025): 100776, doi:https://doi.org/10.1016/j.modpat.2025.100776. TOP 10%

|

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

2025-05-29T09:59:21+10:00April 8th, 2025|

Grover P, Lo SN, Li I, Kuijpers AMJ, Kreidieh F, Williamson A, Amaral T, Dimitriou F, Placzke J, Olino K, Vitale MG, Saiag P, Gutzmer R, Allayous C, Bagge RO, Mattsson J, Asher N, Carter TJ, Meniawy TM, Lawless AR, Czapla JA, Warburton L, Gaudy-Marquest C, Grob JJ, Collins RG, Zhang E, Kessels JI, Neyns B, Mehmi I, Hamid O, Julve M, Furness AJS, Margolin KA, Levi-Ari S, Ressler JM, Haque W, Khattak MA, Wicky A, Roberts-Thomson R, Arance A, Warrier G, Schollenberger MD, Parente P, Chatziioannou E, Lipson EJ, Michielin O, Weber JS, Hoeller C, Larkin J, Atkins MB, Essner R, Johnson DB, Sullivan RJ, Nathan P, Schachter J, Lebbe C, Ascierto PA, Kluger H, Rutkowski P, Dummer R, Garbe C, Lorigan PC, Burton E, Tawbi HA, Haanen J, Carlino MS, Menzies AM, Long GV. Annals of Oncology, (Apr 08 2025), doi:https://doi.org/10.1016/j.annonc.2025.03.021.

|

Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma.

2025-07-24T10:30:29+10:00March 27th, 2025|

Bührer E, Glassee N, Kicinski M, Kennedy OJ, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob J-J, Gutzmer R, Jamal R, van Akkooi ACJ, Gandini S, Valpione S, Suciu S, Robert C, Eggermont AMM, Lorigan P, Mandala M. EJC Skin Cancer, (Mar 27 2025): 100727, doi:https://doi.org/10.1016/j.ejcskn.2025.100727.

|

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study.

2025-05-29T10:21:22+10:00March 23rd, 2025|

Luke JJ, Ascierto PA, Khattak MA, Rutkowski P, Del Vecchio M, Spagnolo F, Mackiewicz J, Merino LdlC, Chiarion-Sileni V, Kirkwood JM, Robert C, Schadendorf D, de Galitiis F, Carlino MS, Dummer R, Mohr P, Odeleye-Ajakaye A, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. European Journal of Cancer, (Mar 23 2025): 115381, doi:https://doi.org/10.1016/j.ejca.2025.115381.

|

Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.

2025-04-07T12:08:39+10:00March 7th, 2025|

Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob J-J, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou Z-Y, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D. Journal of Clinical Oncology, 0, no. 0, (Mar 07 2025): JCO-25-00452, doi:10.1200/jco-25-00452. TOP 10%

|

Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study.

2025-03-27T15:26:42+11:00March 3rd, 2025|

Nassar AH, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman RS, Johnson DB, Grynberg S, Shapira R, Kwan JM, Woodford R, Long GV, Haykal T, Dent S, Kojima Y, Yonemor K, Tandon A, Trevino A, Akhter N, Yang EH, Hui G, Drakaki A, El-Am E, Kozaily E, Al-Hader A, Bou Farhat E, Babu P, Mittra A, Li M, Jones N, Baena J, Juarez Herrera M, Foderaro S, Nana FA, Kim C, Sackstein P, Parikh K, Desai AP, Smith C, Cortellini A, Pinato DJ, Korolewicz J, Lopetegui-Lia N, Funchain P, Choudhary A, Asnani A, Navani V, Meyers D, Stukalin I, Ocejo Gallegos JA, Trent J, Nusrat S, Malvar C, McKay RR, Neilan TG, Choueiri TK, Naqash AR. J Immunother Cancer, 13, no. 3, (Mar 3 2025), doi:10.1136/jitc-2024-009364.

|

FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma.

2025-05-29T11:00:54+10:00March 3rd, 2025|

Zhou L, Barros e Silva MJ, Hsiao E, Eroglu Z, Sandhu S, Samoylenko I, Lo SN, Carlino MS, Au-Yeung G, Gonzalez M, Spillane AJ, Pennington TE, Shannon KF, Kapoor R, Burton EM, Tawbi HA, Amaria RN, Blank CU, Duprat JP, Brito de Paula R, Gyorki DE, Saw RPM, Ch’Ng S, Rawson RV, Scolyer RA, Pires da Silva I, Akkooi ACJv, Long GV, Menzies AM. Journal for ImmunoTherapy of Cancer, 13, no. 3, (Mar 25 2025): e011483, doi:10.1136/jitc-2025-011483.

|

Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.

2025-03-27T14:52:54+11:00February 27th, 2025|

Long GV, Shklovskaya E, Satgunaseelan L, Mao Y, da Silva IP, Perry KA, Diefenbach RJ, Gide TN, Shivalingam B, Buckland ME, Gonzalez M, Caixeiro N, Vergara IA, Bai X, Rawson RV, Hsiao E, Palendira U, Phan TG, Menzies AM, Carlino MS, Quek C, Grimmond SM, Vissers JHA, Yeo D, Rasko JEJ, Khasraw M, Neyns B, Reardon DA, Ashley DM, Wheeler H, Back M, Scolyer RA, Drummond J, Wilmott JS, Rizos H. Nature Medicine, (Feb 27 2025), doi:10.1038/s41591-025-03512-1. TOP 1%

|

Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma.

2025-03-27T15:17:13+11:00February 25th, 2025|

Mo J, Zaremba A, Inderjeeth A-J, El Zeinaty P, Li A, Wicky A, Della Marta N, Marqueste CG, Bohne A-S, Matias M, McNamee N, Festino L, Chen C, Ch’ng S, van Akkooi ACJ, Meda LD, Park JJ, Ascierto PA, Hauschild A, Lee JH, Grob JJ, Mangana J, Guminski A, Michielin O, Xu W, Lebbe C, Sandhu S, Zimmer L, Menzies AM, Lo SN, Long GV, Carlino MS, da Silva IP. European Journal of Cancer, 217(Feb 25 2025), doi:10.1016/j.ejca.2025.115254.

|

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

2025-03-27T13:56:32+11:00February 7th, 2025|

Kennedy OJ, Glassee N, Kicinski M, Bührer E, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob J-J, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. EJC Skin Cancer, (Feb 07 2025): 100284, doi:https://doi.org/10.1016/j.ejcskn.2025.100284.

|

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.

2025-04-07T12:33:21+10:00February 6th, 2025|

Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, Blank CU, Thompson JF, Spillane AJ, Saw RPM, Shannon KF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA, Waddell N, Long GV. Cancer Cell, (Feb 06 2025), doi:https://doi.org/10.1016/j.ccell.2025.01.011. TOP 10%

|

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.

2025-03-27T15:21:31+11:00February 3rd, 2025|

Munoz-Couselo E, Soria Rivas A, Sandhu S, Long GV, Sanmamed MF, Spreafico A, Buchbinder E, Sznol M, Prenen H, Fedenko A, Milhem M, Arance Fernandez AM, Grob JJ, Demidov L, Robert C, Habigt C, Evers S, Sleiman N, Dejardin D, Ardeshir C, Martin N, Boetsch C, Charo J, Teichgraeber V, Kraxner A, Keshelava N, Bechter O. Cancer Res Commun, (Feb 3 2025), doi:10.1158/2767-9764.Crc-24-0601.

|

Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial.

2025-03-31T15:51:39+11:00February 1st, 2025|

Yoon CH, Ross MI, Gastman BR, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak M, Del Vecchio M, de la Cruz Merino L, Mackiewicz J, Chiarion-Sileni V, Schadendorf D, Carlino MS, Zhao Y, Fukunaga-Kalabis M, Krepler C, Eggermont Alexander MM, Gershenwald JE, Sondak VK. Annals of Surgical Oncology, (Feb 01 2025), doi:10.1245/s10434-024-16642-6.

|

Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey.

2025-03-27T13:42:04+11:00January 1st, 2025|

Hauschild A, Garbe C, Ascierto PA, Demidov L, Dreno B, Dummer R, Eggermont A, Forsea A-M, Gebhardt C, Gershenwald JE, Hamid O, Hoeller C, Kandolf L, Kaufmann R, Kirkwood JM, Lebbé C, Long GV, Malvehy J, Martin-Algarra S, McArthur G, Neyns B, Richtig E, Robert C, Schadendorf D, Scolyer R, Sondak VK, Wainstein A, Weichenthal M, Nuti P, Aarts MJB, Arance A, Asher N, Berciano-Guerrero M-A, Berking C, Carlino MS, Dabelić N, Davar D, Espinosa E, Forschner A, Gaide O, Gaudy-Marqueste C, Gavrilova I, Grabbe S, Gutzmer R, Hafner C, Hassel JC, Jacobs C, Jang S, Kähler KC, Kehrer H, Koelblinger P, Leiter U, Lipson EJ, Livingstone E, Luke JJ, Mandalà M, Mangana J, Marić Brozić J, Marquez-Rodas I, Maul LV, Mazilu L, Mehmi I, Meier F, Mesti T, Mitchell TC, Mohr P, Moyers J, Muñoz Couselo E, Najjar YG, Nakamura Y, Ocvirk J, Orlova K, Popescu BC, Popovic A, Posch C, Queirolo P, Ramelyte E, Roberts-Thomson R, Rorive A, Ruhlmann CH, Rutten A, Salama AKS, Samoylenko I, Schilling B, Shalamanova-Deleva G, Siano M, Smithy JW, Stelzhammer P, Suijkerbuijk K, Terheyden P, Teterycz P, Tietze JK, Urbonas V, Utyashev I, van der Veldt AAM, Venter M, Zarour HM, Zimmer L, Zinovev G. The Lancet Oncology, 26, no. 1, (Jan 2025): 12-14, doi:10.1016/S1470-2045(24)00627-2. TOP 10%

|

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.

2025-03-27T11:57:51+11:00January 1st, 2025|

Dimitriou F, Orloff MM, Koch Hein EC, Cheng PF, Hughes IF, Simeone E, Montazeri K, Grover P, Mehmi I, Gerard CL, Gaudy-Marqueste C, Grob J-J, Michielin O, Hamid O, Long GV, Sullivan R, Kapiteijn E, Johnson DB, Ascierto PA, Joshua AM, Carvajal RD, Butler MO, Hassel JC, Dummer R. European Journal of Cancer, 214(Jan 01 2025): 115161, doi:https://doi.org/10.1016/j.ejca.2024.115161.

|

Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma.

2025-03-27T13:34:07+11:00December 8th, 2024|

Handel EE, McKeown J, Wei J, Kankaria RA, Burnette H, Johnson DB, Lawless A, Czapla J, Sullivan RJ, Albrecht LJ, Zimmer L, Mangana J, Dummer R, Kessels JI, Neyns B, Allayous C, Lebbe C, Boatwright C, Mehnert JM, Ottaviano M, Ascierto PA, Czarnecka AM, Rutkowski P, Lo SN, Long GV, Menzies AM, Carlino MS. European Journal of Cancer, (Dec 08 2024), doi:10.1016/j.ejca.2024.115171.

|

Nivolumab (NIVO) plus relatlimab (RELA) vs. NIVO in previously untreated, metastatic, or unresectable melanoma (RELATIVITY-047): 3- year overall survival (OS) and melanoma-specific survival (MSS) results.

2025-04-03T10:22:00+11:00December 1st, 2024|

Tawbi HA, Hodi S, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance AM, Grob JJ, Ratto B, Rodriguez S, Mazzei A, Dolfi S, Long G. Annals of Dermatology and Venereology – FMC, 4, no. 8, Supplement 1, (Dec 01 2024): A349-A50, doi:https://doi.org/10.1016/j.fander.2024.09.415.

|

121MO Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: Final analysis from the randomized part 2 of the phase I/II CA027-002 study.

2025-04-03T10:15:46+11:00December 1st, 2024|

Simonelli M, Butler MO, Ascierto PA, Long GV, Calvo E, Garcia VM, Gebhardt C, Grob JJ, Haydon AM, Quereux G, Walker J, Kumar M, Chakraborty D, Zhu X, Melero I. Immuno-Oncology and Technology, 24(Dec 2024), https://doi.org/10.1016/j.iotech.2024.100750.

|

Efficacy and safety of nivolumab + relatlimab (NIVO+RELA) versus nivolumab + ipilimuab (NIVO+IPI) in the first-line (1L) treatment of advanced melanoma: updated data from an indirect treatment comparison.

2025-04-03T10:08:56+11:00December 1st, 2024|

Schadendorf D, Tawbi HA, Lipson EJ, Hodi S, Ascierto PA, Larkin J, Lao CD, Grob JJ, Ejzykowicz F, Palaia J, Garcia-Horton V, Zhou ZY, Christensen D, Rosenblatt L, McDonald L, Ratto B, Salvatore A, Patel D, Sakkal LA, Dalle S, Long G. Annals of Dermatology and Venereology – FMC, 4, no. 8, Supplement 1, (Dec 01 2024): A82-A83, doi:https://doi.org/10.1016/j.fander.2024.09.510.

|

Nivolumab vs. Placebo in the Adjuvant Treatment of Patients with Stage IIB/C Melanoma: 3-Year Results of the CheckMate 76K (CM 76K) Study.

2025-04-03T09:51:44+11:00December 1st, 2024|

Long G, Del Vecchio M, Hoeller C, Weber J, Grob JJ, Morh P, Grabbe S, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quéreux G, Meniawy T, Ascierto PA, Taube J, Nassar A, Wang W, Kirkwood JM. Annals of Dermatology and Venereology – FMC, 4, no. 8, Supplement 1, (Dec 01 2024): A94-A95, doi:https://doi.org/10.1016/j.fander.2024.09.527.

|

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

2025-11-10T14:48:04+11:00November 21st, 2024|

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. J Clin Oncol, 40, no. 2, (Jan 10 2022): 127-37, doi:10.1200/jco.21.02229. TOP 1%

|

Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo.

2025-03-27T16:27:55+11:00November 19th, 2024|

Reijers ILM, Menzies AM, Lopez-Yurda M, Versluis JM, Rozeman EA, Saw RPM, van Houdt WJ, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Eriksson H, Hospers GAP, Mc Klop W, Acosta AT, Grijpink-Ongering L, Gonzalez M, van der Wal A, Al-Mamgani A, Spillane AJ, Scolyer RA, van de Wiel BA, van Akkooi ACJ, Long GV, Blank CU. European Journal of Cancer, (Nov 19 2024): 115141, doi:https://doi.org/10.1016/j.ejca.2024.115141.

|

Long-term Outcomes among Patients Who Respond within the First Year to Nivolumab plus Ipilimumab or Nivolumab Monotherapy: A Pooled Analysis in 935 Patients.

2025-03-27T16:35:31+11:00November 16th, 2024|

Robert C, Long GV, Larkin J, Wolchok JD, Hassel JC, Schadendorf D, Hodi FS, Lebbé C, Grob JJ, Hyngstrom JR, Wagstaff J, Chesney J, Butler MO, Bechter O, Márquez-Rodas I, Pavlick AC, Durani P, Pe Benito M, Wang P, Postow MA, Ascierto PA. European Journal of Cancer, (Nov 16 2024): 115119, doi:https://doi.org/10.1016/j.ejca.2024.115119.

|

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

2025-03-27T10:47:19+11:00November 14th, 2024|

Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, Dummer R, Garbe C, Gershenwald JE, Gogas H, Guckenberger M, Haanen J, Hamid O, Hauschild A, Höller C, Lebbé C, Lee RJ, Long GV, Lorigan P, Couselo EM, Nathan P, Robert C, Romano E, Schadendorf D, Sondak V, Suijkerbuijk KPM, van Akkooi ACJ, Michelin O, Ascierto PA. Annals of Oncology, (Nov 14 2024), doi:10.1016/j.annonc.2024.11.006. TOP 10%

|

A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases

2025-03-27T11:48:52+11:00November 10th, 2024|

DePalo DK, Dugan MM, Naqvi SMH, Ollila DW, Hieken TJ, Block MS, van Houdt WJ, Wouters M, Reijers SJM, Asher N, Broman KK, Duncan Z, Anderson M, Gyorki DE, Snow H, Held J, Farma JM, Vetto JT, Hui JYC, Kolbow M, Saw RPM, Lo SN, Long GV, Thompson JF, Kim Y, Karapetyan L, Ny L, van Akkooi ACJ, Bagge RO, Zager JS. Cancer, (Nov 10 2024), doi:10.1002/cncr.35636.

|

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.

2025-03-27T14:47:50+11:00November 6th, 2024|

Long GV, Larkin J, Schadendorf D, Grob J-J, Lao CD, Márquez-Rodas I, Wagstaff J, Lebbé C, Pigozzo J, Robert C, Ascierto PA, Atkinson V, Postow MA, Atkins MB, Sznol M, Callahan MK, Topalian SL, Sosman JA, Kotapati S, Thakkar PK, Ritchings C, Benito MP, Re S, Soleymani S, Hodi FS. Journal of Clinical Oncology, (Nov 06 2024): JCO.24.00400, doi:10.1200/jco.24.00400. TOP 10%

|

Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.

2025-07-31T12:46:31+10:00November 1st, 2024|

Eggermont AM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Lorigan P, Grebennik D, Kreplere C, Marreaud S, Suciu S, Robert C. Eur J Cancer, 211(Nov 2024): 114327, doi:10.1016/j.ejca.2024.114327.

|

The Prognostic Significance of Tumoral Melanosis

2025-08-05T11:01:43+10:00October 2nd, 2024|

Potter Alison J, Ferguson Peter M, Lo Serigne N, Ahmed T, Rawson Robert V, Thompson John F, Long Georgina V, Scolyer Richard A. Journal of Cutaneous Pathology, (Oct 02 2024), doi:https://doi.org/10.1111/cup.14727.

|

A brave new framework for glioma drug development.

2025-07-31T14:37:24+10:00October 1st, 2024|

Hotchkiss KM, Karschnia P, Schreck KC, Geurts M, Cloughesy TF, Huse J, Duke ES, Lathia J, Ashley DM, Nduom EK, Long G, Singh K, Chalmers A, Ahluwalia MS, Heimberger A, Bagley S, Todo T, Verhaak R, Kelly PD, Hervey-Jumper S, de Groot J, Patel A, Fecci P, Parney I, Wykes V, Watts C, Burns TC, Sanai N, Preusser M, Tonn JC, Drummond KJ, Platten M, Das S, Tanner K, Vogelbaum MA, Weller M, Whittle JR, Berger MS, Khasraw M. The Lancet Oncology, 25, no. 10, (Oct 2024): e512-e19, doi:10.1016/S1470-2045(24)00190-6. TOP 10%

|

Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy

2025-08-05T14:53:58+10:00September 28th, 2024|

Woodford R, McKeown J, Hoeijmakers LL, Mangana J, Dimitriou F, Allayous C, Zaman F, Aya F, Marsiglio J, Goodman R, Rayson V, Placzke J, Kessels J, Ramalyte E, Haque W, Wilson I, Trojaniello C, Benannoune N, Roberts-Thomson R, Robert C, Blank CU, Dummer R, Lebbe C, Haydon A, Arance A, Hu-Lieskovan S, Johnson DB, McArthur GA, Rutkowski P, Neyns B, Sullivan RJ, Weber J, Carlino MS, Ascierto PA, Lo S, Long GV, Menzies AM. European Journal of Cancer, 212(Sep 28 2024), doi:10.1016/j.ejca.2024.115055.

|

1090P High concurrent interferon gamma signature expression in the primary tumor and lymph node metastasis is associated with superior outcome upon neoadjuvant ipilimumab + nivolumab in stage III melanoma

2025-08-05T16:17:56+10:00September 27th, 2024|

Hoeijmakers L, Dimitriadis P, Cornelissen S, Reijers I, van de Wiel B, Scolyer RA, Saw RPM, Spillane AJ, Broeks A, Lopez-Yurda M, Grijpink-Ongering L, Hospers G, Menzies AM, van Akkooi ACJ, Van Houdt W, Long GV, Blank CU. Annals of Oncology, 35(Sep 24 2024): S721-S22, doi:10.1016/j.annonc.2024.08.1158.

|

1092P Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047

2025-08-05T16:41:04+10:00September 24th, 2024|

Schadendorf D, Tawbi HA, Hodi FS, Lipson EJ, Ascierto PA, Medina Soto FA, Maio M, Hernberg M, Mackiewicz J, Prey S, Mujika Eizmendi MK, Atkinson VG, Hassel JC, Cinat G, Keidel S, Rodriguez S, Wang PT, Dolfi S, Long GV. Annals of Oncology, 35(Sep 24 2024): S723-S24, doi:10.1016/j.annonc.2024.08.1160.

|

LBA41 Long-term survival with neoadjuvant therapy in melanoma: Updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

2025-08-05T16:27:43+10:00September 24th, 2024|

Long GV, Blank CU, Amaria RN, Hieken TJ, Sandhu SK, Barros MJ, Mitchell TCC, Eroglu Z, Samoylenko IV, Rutkowski P, Johnson D, Pires da Silva I, Perry KA, Tawbi HA, Block MS, Ascierto PA, Burton E, van Akkooi ACJ, Scolyer RA, Menzies AM. Annals of Oncology, 35(Sep 24 2024): S1232, doi:10.1016/j.annonc.2024.08.2282.

|

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

2025-08-05T14:50:50+10:00September 15th, 2024|

Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Sandhu S, Lebbé C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J. New England Journal of Medicine, (Sep 15 2024), doi:doi:10.1056/NEJMoa2407417. TOP 1%

|

Towards evidence-based skin checks

2025-08-05T10:26:49+10:00September 6th, 2024|

Martin L, Guitera P, Long G, Scolyer R, Cust A. Med Journal of Australia, (Oct 07 2024), doi:doi: 10.5694/mja2.52443. TOP 10%

|

Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)

2025-08-05T10:20:31+10:00September 3rd, 2024|

Mandalà M, Ferrari A, Brecht IB, Suijkerbuijk KP, Maschke L, Giannarelli D, Indini A, Ubaldi M, Pecci G, Atkinson V, Helgadottir H, Chiaravalli S, Benannoune N, Robert C, Teterycz P, Rutkowski P, Puig S, Madonna G, Kebudi R, Grynberg S, Arantes LM, Bien E, Krawczyk M, Pasquale MD, Dierselhuis MP, Massi D, Long GV, Ascierto PA, Eggermont AMM. Eur J Cancer, 211(Sep 3 2024): 114305, doi:10.1016/j.ejca.2024.114305.

|

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.

2025-07-31T16:12:04+10:00August 13th, 2024|

Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob JJ, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou ZY, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D. J Clin Oncol, (Aug 13 2024): Jco2401125, doi:10.1200/jco.24.01125. TOP 10%

|

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

2025-07-31T11:00:47+10:00August 12th, 2024|

Bührer E, Kicinski M, Mandala M, Pe M, Long GV, Atkinson V, Blank CU, Haydon A, Dalle S, Khattak A, Carlino MS, Meshcheryakov A, Sandhu S, Puig S, Schadendorf D, Jamal R, Rutkowski P, van den Eertwegh AJM, Coens C, Grebennik D, Krepler C, Robert C, Eggermont AMM. The Lancet Oncology, 25, no. 9, (Aug 12 2024): 1202-12, doi:10.1016/S1470-2045(24)00338-3.

|

Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238

2025-08-05T14:32:41+10:00August 5th, 2024|

Weber J, Vecchio MD, Mandalá M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob J-J, Chiarion-Sileni V, Márquez-Rodas I, Butler MO, Giacomo AMD, Cruz-Merino Ldl, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Long GV, Lobo M, Askelson M, Ascierto PA, Larkin J. Journal of Clinical Oncology, (Aug 05 2024): JCO.23.01448, doi:10.1200/jco.23.01448. TOP 10%

|

Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

2025-08-05T16:29:31+10:00June 10th, 2024|

Long GV, Hauschild A, Santinami M, Kirkwood JM, Atkinson V, Mandala M, Merelli B, Sileni VC, Nyakas M, Haydon A, Dutriaux C, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Larkin J, Tan M, Adnaik SB, Burgess P, Jandoo T, Dummer R. New England Journal of Medicine, (Jun 19 2024), doi:doi:10.1056/NEJMoa2404139. TOP 1%

|

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

2025-07-31T10:36:06+10:00June 2nd, 2024|

Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, Hoeijmakers LL, Saw RPM, Lijnsvelt JM, Maher NG, Pulleman SM, Gonzalez M, Torres Acosta A, van Houdt WJ, Lo SN, Kuijpers AMJ, Spillane A, Klop WMC, Pennington TE, Zuur CL, Shannon KF, Seinstra BA, Rawson RV, Haanen J, Ch’ng S, Naipal KAT, Stretch J, van Thienen JV, Rtshiladze MA, Wilgenhof S, Kapoor R, Meerveld-Eggink A, Grijpink-Ongering LG, van Akkooi ACJ, Reijers ILM, Gyorki DE, Grünhagen DJ, Speetjens FM, Vliek SB, Placzke J, Spain L, Stassen RC, Amini-Adle M, Lebbé C, Faries MB, Robert C, Ascierto PA, van Rijn R, van den Berkmortel F, Piersma D, van der Westhuizen A, Vreugdenhil G, Aarts MJB, Stevense-den Boer MAM, Atkinson V, Khattak M, Andrews MC, van den Eertwegh AJM, Boers-Sonderen MJ, Hospers GAP, Carlino MS, de Groot JB, Kapiteijn E, Suijkerbuijk KPM, Rutkowski P, Sandhu S, van der Veldt AAM, Long GV. N Engl J Med, (Jun 2 2024), doi:10.1056/NEJMoa2402604. TOP 1%

|

Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma

2025-08-05T10:12:01+10:00May 31st, 2024|

Luke JJ, Long GV, Robert C, Carlino MS, Choueiri TK, Haas NB, O’Brien M, Paz-Ares L, Peters S, Powles T, Leiby MA, Lin J, Zhao Y, Krepler C, Perini RF, Catherine Pietanza M, Samkari A, Gruber T, Ibrahim N, Eggermont AMM. European Journal of Cancer, (May 31 2024): 114146, doi:https://doi.org/10.1016/j.ejca.2024.114146.

|

Neoadjuvant Triplet Immune Checkpoint Blockade in Newly Diagnosed Glioblastoma.

2025-04-03T14:58:02+11:00April 28th, 2024|

Long G, Wilmott J, Shklovskaya E, Satgunseelan L, Mao Y, Perry K, Diefenbach R, Gide T, Shivalingam B, Buckland ME, Gonzalez M, Caixeiro NJ, Vergara I, Bai X, Hsiao E, Rawson R, da Silva I, Palendira U, Phan T, Menzies A, Carlino M, Quek C, Grimmond SM, Vissers J, Yeo D, Rasko JE, Khasraw M, Neytns B, Reardon D, Ashley DM, Wheeler H, Back M, Drummond J, Scolyer R, Rizos H. Nature Portfolio, (Preprint Apr 28 2024), doi:https://doi.org/10.21203/rs.3.rs-4255559/v1.

|

Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.

2025-04-03T15:11:52+11:00April 18th, 2024|

Luke JJ, Davar D, Andtbacka RH, Bhardwaj N, Brody JD, Chesney J, Coffin R, de Baere T, de Gruijl TD, Fury M, Goldmacher G, Harrington KJ, Kaufman H, Kelly CM, Khilnani AD, Liu K, Loi S, Long GV, Melero I, Middleton M, Neyns B, Pinato DJ, Sheth RA, Solomon SB, Szapary P, Marabelle A. J Immunother Cancer, 12, no. 4, (Apr 18 2024), doi:10.1136/jitc-2023-008378.

|

POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis

2025-08-05T10:33:55+10:00March 18th, 2024|

Menzies AM, Long GV, Kohn A, Tawbi H, Weber J, Flaherty K, McArthur GA, Ascierto PA, Pfluger Y, Lewis K, Tsai KK, Hamid O, Prenen H, Fein L, Wang E, Guenzel C, Zhang F, Kleha JF, di Pietro A, Davies MA. Neuro-Oncology Advances, 6, no. 1, (Mar 18 2024), doi:10.1093/noajnl/vdae033. VDAE033

|

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.

2024-05-09T12:13:11+10:00March 13th, 2024|

Schadendorf D, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak M, Del Vecchio M, de la Cruz Merino L, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob J-J, Dummer R, Carlino MS, Zhao Y, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Scolyer RA. Journal of Immunotherapy of Cancer.

|

Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.

2025-04-03T15:06:45+11:00March 7th, 2024|

Luke JJ, Ascierto PA, Khattak MA, Merino LdlC, Vecchio MD, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob J-J, Galitiis Fd, Schadendorf D, Carlino MS, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. Journal of Clinical Oncology, 0, no. 0, (Mar 07 2024): JCO.23.02355, doi:10.1200/jco.23.02355. TOP 10%

|

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma

2024-06-03T15:46:56+10:00March 1st, 2024|

Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, Váraljai R, Lodde G, Placke JM, Krefting F, Zaremba A, Ugurel S, Roesch A, Schulz C, Berking C, Pöttgen C, Menzies AM, Long GV, Dummer R, Livingstone E, Schadendorf D, Zimmer L. European Journal of Cancer, doi:10.1016/j.ejca.2024.113976.

|

Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.

2025-04-03T12:31:28+11:00March 1st, 2024|

Jacques SK, McKeown J, Grover P, Johnson DB, Zaremba A, Dimitriou F, Weiser R, Farid M, Namikawa K, Sullivan RJ, Rutkowski P, Lebbe C, Hamid O, Zager JS, Michielin O, Neyns B, Nakamura Y, Robert C, Mehnert J, Ascierto PA, Bhave P, Park B, Zimmer L, Mangana J, Mooradian M, Placzke J, Allayous C, Glitza Oliva IC, Mehmi I, Depalo D, Wicky A, Schwarze JK, Roy S, Boatwright C, Vanella V, Long GV, Menzies AM, Lo SN, Carlino MS. Eur J Cancer, 199(Mar 2024): 113563, doi:10.1016/j.ejca.2024.113563.

|

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.

2025-04-03T16:32:40+11:00February 17th, 2024|

Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Lancet, 403, no. 10427, (Feb 17 2024): 632-44, doi:10.1016/s0140-6736(23)02268-7. TOP 1%

|

Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe.

2025-04-03T15:16:08+11:00February 5th, 2024|

Maul LV, Jamiolkowski D, Lapides RA, Mueller AM, Hauschild A, Garbe C, Lorigan P, Gershenwald JE, Ascierto PA, Long GV, Wang-Evers M, Scolyer RA, Saravi B, Augustin M, Navarini AA, Legge S, Németh IB, Jánosi Á J, Mocellin S, Feller A, Manstein D, Zink A, Maul JT, Buja A, Adhikari K, Roider E. JAMA Netw Open, 7, no. 2, (Feb 5 2024): e2356479, doi:10.1001/jamanetworkopen.2023.56479. TOP 10%

|

Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

2025-04-03T12:50:35+11:00February 1st, 2024|

Kennedy OJ, Glassee N, Kicinski M, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Giacomo AMD, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Gandini S, Buhrer E, Suciu S, Robert C, Eggermont AMM, Mandala M, Lorigan P, Valpione S. Eur J Cancer, 201(Feb 1 2024): 113585, doi:10.1016/j.ejca.2024.113585.

|

Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.

2025-05-08T13:09:30+10:00January 20th, 2024|

Taylor AM, McKeown J, Dimitriou F, Jacques SK, Zimmer L, Allayous C, Yeoh H-L, Haydon A, Ressler JM, Galea C, Woodford R, Kahler K, Hauschild A, Festino L, Hoeller C, Schwarze JK, Neyns B, Wicky A, Michielin O, Placzke J, Rutkowski P, Johnson DB, Lebbe C, Dummer R, Ascierto PA, Lo S, Long GV, Carlino MS, Menzies AM. European Journal of Cancer, (Jan 20 2024): 113561, doi:https://doi.org/10.1016/j.ejca.2024.113561.

|

Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.

2025-05-08T12:31:55+10:00January 19th, 2024|

Mandalà M, Lorigan P, Sergi MC, Benannoune N, Serra P, Vitale MG, Giannarelli D, Arance AM, Couselo EM, Neyns B, Tucci M, Guida M, Spagnolo F, Rossi E, Occelli M, Queirolo P, Quaglino P, Depenni R, Merelli B, Placzke J, Di Giacomo AM, del Vecchio M, Indini A, da Silva IP, Menzies AM, Long GV, Robert C, Rutkowski P, Ascierto PA. European Journal of Cancer, (Jan 19 2024): 113542, doi:https://doi.org/10.1016/j.ejca.2024.113542.

|

Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.

2025-05-08T09:53:57+10:00January 11th, 2024|

Brahmer JR, Long GV, Hamid O, Garon EB, Herbst RS, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri TK, Cohen EEW, Diaz LA, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani PL, Jafari N, Bird S, Snyder E, Gause C, Bracco OL, Pietanza MC, Gruber T, Ribas A. European Journal of Cancer, (Jan 11 2024): 113530, doi:https://doi.org/10.1016/j.ejca.2024.113530.

|

The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects.

2025-05-08T10:00:24+10:00December 23rd, 2023|

Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, Bergwelt-Baildon Mv, Subklewe M, Tomsitz D, Ascierto PA, Dummer R, Gogas H, Lebbé C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Zimmer L, Eigentler T, Grabbe S, Forschner A, Kähler KC, Milani V, Pföhler C, Hassel J, Gutzmer R, Loquai C, Routy B, Furness AJS, Blank C, Wolchok JD, French LE, Keller-Stanislawski B, Hauschild A, Heinzerling L. European Journal of Cancer, (Dec 23 2023): 113505, doi:https://doi.org/10.1016/j.ejca.2023.113505.

|

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.

2025-05-08T12:44:24+10:00December 9th, 2023|

Schadendorf D, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak M, Del Vecchio M, de la Cruz Merino L, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob J-J, Dummer R, Carlino MS, Zhao Y, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Scolyer RA. Journal of Immunotherapy of Cancer, (accepted Dec 09 2023).

|

Neoadjuvant relatlimab and nivolumab in resectable melanoma.

2025-05-08T13:06:19+10:00December 1st, 2023|

Tawbi HA, Hodi S, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas H, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Ratto B, Rodriguez S, Xu Y, Wang P, Dolfi S, Long G. Journal of the European Academy of Dermatology & Venereology, 3, no. 8, Supplement 1, (Dec 01 2023): A351-A53, doi:https://doi.org/10.1016/j.fander.2023.09.600. TOP 10%

|

A tailored approach to horizon scanning for cancer medicines.

2025-05-08T12:56:15+10:00November 20th, 2023|

Soon JA, To YH, Alexander M, Trapani K, Ascierto PA, Athan S, Brown MP, Burge M, Haydon A, Hughes B, Itchins M, John T, Kao S, Koopman M, Li BT, Long GV, Loree JM, Markman B, Meniawy TM, Menzies AM, Nott L, Pavlakis N, Petrella TM, Popat S, Tie J, Xu W, Yip D, Zalcberg J, Solomon BJ, Gibbs P, McArthur GA, Franchini F, Ijzerman M. Journal of Cancer Policy, (Nov 20 2023): 100441, doi:https://doi.org/10.1016/j.jcpo.2023.100441.

|

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.

2025-05-08T10:14:54+10:00November 17th, 2023|

Hepner A, Versluis JM, Wallace R, Allayous C, Brown LJ, Trojaniello C, Gerard CL, Jansen YJL, Bhave P, Neyns B, Haydon A, Michielin O, Mangana J, Klein O, Shoushtari AN, Warner AB, Ascierto PA, McQuade JL, Carlino MS, Zimmer L, Lebbe C, Johnson DB, Sandhu S, Atkinson V, Blank CU, Lo SN, Long GV, Menzies AM. European Journal of Cancer, 196(Nov 17 2023), doi:10.1016/j.ejca.2023.113441.

|

Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging.

2025-05-08T10:12:00+10:00November 15th, 2023|

Gjorup CA, Woodford R, Li I, Carlino MS, Ch’ng S, Chung D, Hsiao E, Lo SN, London K, Long GV, Menzies AM, Nieweg OE, Pennington TE, Rtshiladze MA, Saw RPM, Scolyer RA, Shannon KF, Spillane AJ, Stretch JR, Thompson JF, Varey AHR, van Akkooi ACJ. Ann Surg Oncol, (Nov 15 2023), doi:10.1245/s10434-023-14526-9.

|

Long-Term Outcomes and Persistent Toxicities Following BRAF/MEK Inhibitor Therapy for Advanced Melanoma.

2025-09-10T12:15:06+10:00September 22nd, 2023|

Goodman RS, Di Guardo L, Maurichi A, Kirwin B, Khattak AM, Vanella V, Lee J, Lawless A, Czapla JA, Spagnoletti A, Ambrosini M, Livingstone E, Long GV, Sullivan RJ, Carlino MS, Atkinson V, Trojanello C, Ascierto PA, Schadendorf D, Warburton L, Menzies AM, Santinami M, Johnson DB. European Journal of Cancer: 113354, doi:https://doi.org/10.1016/j.ejca.2023.113354.

|

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

2025-09-02T16:43:31+10:00August 31st, 2023|

Diab A, Gogas H, Sandhu S, Long GV, Ascierto PA, Larkin J, Sznol M, Franke F, Ciuleanu TE, Pereira C, Couselo EM, Damian FB, Schenker M, Perfetti A, Lebbe C, Quéreux G, Meier F, Curti BD, Rojas C, Arriaga Y, Yang H, Zhou M, Ravimohan S, Statkevich P, Tagliaferri MA, Khushalani NI. Journal of Clinical Oncology, 0, no. 0: JCO.23.00172, doi:10.1200/jco.23.00172. TOP 10%

|

Cutaneous melanoma: a contemporary overview.

2025-05-01T09:29:57+10:00July 24th, 2023|

Georgina V Long, Susan M Swetter, Alexander M Menzies, Jeffrey E Gershenwald, Richard A Scolyer. Lancet 2023 Jul 24;S0140-6736(23)00821-8. doi: 10.1016/S0140-6736(23)00821-8.

|

Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma in Patients with Concomitant Chronic Lymphocytic Leukemia

2025-09-02T16:21:21+10:00July 4th, 2023|

Cass SH, Tobin JWD, Seo YD, Gener-Ricos G, Keung EZ, Burton EM, Davies MA, McQuade JL, Lazar AJ, Mason R, Millward M, Sandhu S, Khoo C, Warburton L, Guerra V, Haydon A, Dearden H, Menzies AM, Carlino M, Smith JL, Mollee P, Burgess M, Mapp S, Keane C, Atkinson V, Parikh SA, Markovic SN, Ding W, Call TG, Hampel PJ, Long GV, Wargo JA, Ferrajoli A. Ann Oncol, doi:10.1016/j.annonc.2023.06.007. TOP 10%

|

Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.

2025-04-24T12:59:04+10:00July 4th, 2023|

Cass SH, Tobin JWD, Seo YD, Gener-Ricos G, Keung EZ, Burton EM, Davies MA, McQuade JL, Lazar AJ, Mason R, Millward M, Sandhu S, Khoo C, Warburton L, Guerra V, Haydon A, Dearden H, Menzies AM, Carlino M, Smith JL, Mollee P, Burgess M, Mapp S, Keane C, Atkinson V, Parikh SA, Markovic SN, Ding W, Call TG, Hampel PJ, Long GV, Wargo JA, Ferrajoli A. Ann Oncol, (Jul 4 2023), doi:10.1016/j.annonc.2023.06.007. TOP 10%

|

Abstract CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial

2025-08-05T17:14:00+10:00May 29th, 2023|

Khattak A, Carlino M, Meniawy T, Ansstas G, Medina T, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran T, Cowey C, Pecora A, Segar J, Atkinson V, Gibney GT, Luke J, Thomas S, Buchbinder E, Hou P, Zhu L, Zaks T, Brown M, Aanur P, Meehan RS, Weber JS. Cancer Research, 83, no. 8_Supplement, (May 29 2023): CT001-CT01, doi:10.1158/1538-7445.Am2023-ct001.

|

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.

2025-04-24T13:43:51+10:00May 16th, 2023|

Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA, Burton EM, Dreno B, Eggermont AMM, Hauschild A, Hoeller C, Kaufmann R, Lebbe C, Mandala M, Menzies AM, Moreno D, Michielin O, Nathan P, Patel SP, Robert C, Schadendorf D, Lorigan PC, Scolyer RA, Tawbi HA, van de Wiel BA, Blank C, Long GV. Nature Medicine, (May 16 2023), doi:10.1038/s41591-023-02336-1. TOP 1%

|

Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.

2025-04-28T11:26:29+10:00May 16th, 2023|

Zarif TE, Nassar AH, Adib E, Fitzgerald BG, Huang J, Mouhieddine TH, Rubinstein PG, Nonato T, McKay RR, Li M, Mittra A, Owen DH, Baiocchi RA, Lorentsen M, Dittus C, Dizman N, Falohun A, Abdel-Wahab N, Diab A, Bankapur A, Reed A, Kim C, Arora A, Shah NJ, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Ghazal BA, Saeed A, Drolen C, Lechner MG, Drakaki A, Baena J, Nebhan CA, Haykal T, Morse MA, Cortellini A, Pinato DJ, Pria AD, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Nana FA, Lopetegui-Lia N, Dima D, Dobbs RW, Funchain P, Saleem R, Woodford R, Long GV, Menzies AM, Genova C, Barletta G, Puri S, Florou V, Idossa D, Saponara M, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Reid EG, Chiao EY, Sharon E, Johnson DB, Ramaswami R, Bower M, Emu B, Marron TU, Choueiri TK, Baden LR, Lurain K, Sonpavde GP, Naqash AR. Journal of Clinical Oncology, (May 16 2023): JCO.22.02459, doi:10.1200/jco.22.02459. TOP 10%

|

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.

2023-05-14T19:44:01+10:00March 15th, 2023|

Reijers ILM, Rao D, Versluis JM, Menzies AM, Dimitriadis P, Wouters MW, Spillane AJ, Klop WMC, Broeks A, Bosch LJW, Lopez-Yurda M, van Houdt WJ, Rawson RV, Grijpink-Ongering LG, Gonzalez M, Cornelissen S, Bouwman J, Sanders J, Plasmeijer E, Elshot YS, Scolyer RA, van de Wiel BA, Peeper DS, van Akkooi ACJ, Long GV, Blank CU. J Exp Med. 2023 May 1;220(5):e20221952. doi: 10.1084/jem.20221952. Epub 2023 Mar 15. PMID: 36920329; PMCID: PMC10037109.

|

Clinical features and outcomes of cardiac involvement in patients with cancer treated with immune checkpoint inhibitors.

2023-05-14T19:23:51+10:00March 1st, 2023|
Sarah Abou Alaiwi, Amin Nassar, Talal Zarif, Edward El-Am, Ryan Denu, Walid Macaron, Carmel Malvar, Alessio Cortellini, James Korolewicz, Paul Sackstein, Frank Aboubakar Nana, Rachel Woodford, Georgina V. Long, Jennifer Kwan, Shirly Grynberg, Ronnie Shapira, Mercedes Herrera-Juárez, Simone Foderaro, Alexi Vasbinder, Aarti Asnani, Ankita Tandon, Salim Hayek, Tomas G. Neilan, Toni Choueiri, and Abdul-Rafeh Naqash.  J Am Coll Cardiol. 2023 Mar, 81 (8_Supplement) 2338.https://doi.org/10.1016/S0735-1097(23)02782-1
|

Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy.

2023-05-15T20:22:46+10:00February 15th, 2023|

Lee H, Ferguson AL, Quek C, Vergara IA, Pires daSilva I, Allen R, Gide TN, Conway JW, Koufariotis LT, Hayward NK, Waddell N, Carlino MS, Menzies AM, Saw RPM, Shklovskaya E, Rizos H, Lo S, Scolyer RA, Long GV, Palendira U, Wilmott JS. Clin Cancer Res. 2023 Feb 15:CCR-22-2657. doi: 10.1158/1078-0432.CCR-22-2657. Epub ahead of print. PMID: 36790412.

|

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

2023-05-14T16:06:01+10:00February 13th, 2023|

Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dréno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D, Dolfi S, Mitra P, Suryawanshi S, Grob J-J.  Journal of Clinical Oncology, (Feb 13 2023): JCO.22.02072, doi:10.1200/jco.22.02072.

|

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.

2023-05-14T16:54:39+10:00February 1st, 2023|

Wilmott JS, Tawbi H, Engh JA, Amankulor NM, Shivalingam B, Banerjee H, Vergara IA, Lee H, Johansson PA, Ferguson PM, Saiag P, Robert C, Grob JJ, Butterfield LH, Scolyer RA, Kirkwood JM, Long GV, Davies MA. Clin Cancer Res, 29, no. 3, (Feb 1 2023): 521-31, doi:10.1158/1078-0432.Ccr-22-2581

|

IFNγ signaling sensitizes melanoma cells to BH3 Mimetics.

2023-05-14T16:40:18+10:00February 1st, 2023|

Ming Z, Lim SY, Stewart A, Pedersen B, Shklovskaya E, Menzies AM, Carlino MS, Kefford RF, Lee JH, Scolyer RA, Long GV, Rizos H.  Journal of Investigative Dermatology, (Feb 01 2023), doi:https://doi.org/10.1016/j.jid.2023.01.017.

|

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

2023-05-14T16:01:42+10:00January 18th, 2023|

Versluis JM, Menzies AM, Sikorska K, Rozeman EA, Saw RPM, van Houdt WJ, Eriksson H, Klop WMC, Ch’ng S, van Thienen JV, Mallo H, Gonzalez M, Torres Acosta A, Grijpink-Ongering LG, van der Wal A, Bruining A, van de Wiel BA, Scolyer RA, Haanen J, Schumacher TN, van Akkooi ACJ, Long GV, Blank CU.  Ann Oncol, (Jan 18 2023), doi:10.1016/j.annonc.2023.01.004

|

Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.

2023-05-14T15:15:25+10:00January 10th, 2023|

Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA.  Nature, (Jan 10 2023), doi:10.1038/s41586-022-05632-x.

 

|

Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma

2023-05-14T11:12:23+10:00January 9th, 2023|

Wong SK, Blum SM, Sun X, Pires Da Silva I, Zubiri L, Ye F, Bai K, Zhang K, Ugurel S, Zimmer L, Livingstone E, Schadendorf D, Serra-Bellver P, Muñoz-Couselo E, Ortiz C, Lostes J, Huertas RM, Arance A, Pickering L, Long GV, Carlino MS, Buchbinder EI, Vázquez-Cortés L, Jara-Casas D, Márquez-Rodas I, González-Espinoza IR, Balko JM, Menzies AM, Sullivan RJ, Johnson DB. European Journal of Cancer, 2022, ISSN 0959-8049

|

Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases.

2023-01-21T22:57:07+11:00December 7th, 2022|

Wilmott JS, Tawbi H, Engh JA, Amankulor NM, Shivalingam B, Banerjee H, Vergara IA, Lee H, Johansson PA, Ferguson PM, Saiag P, Robert C, Grob JJ, Butterfield LH, Scolyer RA, Kirkwood JM, Long GV, Davies MA. Clin Cancer Res. 2022 Dec 7:CCR-22-2581. doi: 10.1158/1078-0432.CCR-22-2581. Epub ahead of print. PMID: 36477181.

|

BRAF inhibitor cessation prior to disease progression in metastatic melanoma: long term outcomes.

2022-11-20T14:37:39+11:00November 9th, 2022|

J. Lee, T. Ahmed, A. Maurichi, L. Di Guardo, A.M. Stagno, L. Warburton, A. Taylor, E. Livingstone, S. Rehman, A. Khattak, K. Kahler, V. Vanella, V. Atkinson, M. Millward, D. Schadendorf, D.B. Johnson, P.A. Ascierto, A. Hauschild, S.N. Lo, G.V. Long, A.M. Menzies, M.S. Carlino. European Journal of Cancer, 2022, ISSN 0959-8049, https://doi.org/10.1016/j.ejca.2022.11.009.

|

Combination of the STING Agonist MIW815 and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-label, Multicenter, Phase Ib Study.

2022-11-20T14:01:27+11:00October 25th, 2022|

Meric-Bernstam F, Sweis RF, Kasper S, Hamid O, Bhatia S, Dummer R, Stradella A, Long GV, Spreafico A, Shimizu T, Steeghs N, Luke JJ, McWhirter SM, Müller T, Nair N, Lewis N, Chen X, Bean A, Kattenhorn L, Pelletier M, Sandhu S. Clin Cancer Res. 2022 Oct 25:CCR-22-2235. doi: 10.1158/1078-0432.CCR-22-2235. Epub ahead of print. PMID: 36282874.

|

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.

2022-11-20T09:47:33+11:00October 18th, 2022|

Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob J-J, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto PA.  The Lancet Oncology, (Oct 18 2022)

|

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.

2022-11-20T13:34:01+11:00October 7th, 2022|

Serra-Bellver P, Versluis JM, Oberoi HK, Zhou C, Slattery TD, Khan Y, Patrinely JR, Pires da Silva I, Martínez-Vila C, Cook N, Graham DM, Carlino MS, Menzies AM, Arance AM, Johnson DB, Long GV, Pickering L, Larkin JMG, Blank CU, Lorigan P. Eur J Cancer. 2022 Oct 7;176:121-132. doi: 10.1016/j.ejca.2022.09.004. Epub ahead of print. PMID: 36215945.

 

|

Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.

2022-11-19T22:44:45+11:00October 3rd, 2022|

Muhammad A. Khattak, Jason J. Luke, Georgina V. Long, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Caroline Robert, Jean-Jacques Grob, Luis de la Cruz Merino, Michele Del Vecchio, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion-Sileni, Matteo S. Carlino, Peter Mohr, Federica De Galitiis, Merrick I. Ross, Zeynep Eroglu, Ke Chen, Ruixuan Jiang, Mizuho Fukunaga-Kalabis, Clemens Krepler, Alexander M.M. Eggermont, John M. Kirkwood. European Journal of Cancer, 2022, ISSN 0959-8049

|

Obesity is associated with altered tumor metabolism in metastatic melanoma.

2022-11-19T22:24:52+11:00September 27th, 2022|

Hahn AW, Menk AV, Rivadeneira DB, Augustin RC, Xu M, Li J, Wu X, Mishra AK, Gide TN, Quek C, Zang Y, Spencer CN, Menzies AM, Daniel CR, Hudgens CW, Nowicki T, Haydu LE, Khan MAW, Gopalakrishnan V, Burton EM, Malke J, Simon JM, Bernatchez C, Putluri N, Woodman SE, Gopal Y N V, Guerrieri R, Fischer GM, Wang J, Wani KM, Thompson JF, Lee JE, Hwu P, Ajami N, Gershenwald JE, Long GV, Scolyer RA, Tetzlaff MT, Lazar AJ, Schadendorf D, Wargo JA, Kirkwood JM, DeBerardinis RJ, Liang H, Futreal A, Zhang J, Wilmott JS, Peng W, Davies MA, Delgoffe GM, Najjar YG, McQuade JL. Clin Cancer Res. 2022 Sep 27:CCR-22-2661. doi: 10.1158/1078-0432.CCR-22-2661. Epub ahead of print. PMID: 36166093.

|

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).

2022-11-19T22:17:24+11:00September 26th, 2022|

Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, Pigozzo J, Gogas H, Dalle S, Meyer N, Ascierto PA, Sandhu S, Eigentler T, Gutzmer R, Hassel JC, Robert C, Carlino MS, Di Giacomo AM, Butler MO, Muñoz-Couselo E, Brown MP, Rutkowski P, Haydon A, Grob JJ, Schachter J, Queirolo P, de la Cruz-Merino L, van der Westhuizen A, Menzies AM, Re S, Bas T, de Pril V, Braverman J, Tenney DJ, Tang H, Long GV. J Clin Oncol. 2022 Sep 26:JCO2200533. doi: 10.1200/JCO.22.00533. Epub ahead of print. PMID: 36162037.

|

Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series.

2022-11-19T22:01:59+11:00September 23rd, 2022|

Smith JL, Menzies AM, Cohen JV, Mut-Lloret M, Ozgun A, Spain L, Park J, Quach HT, Pallan L, McQuade J, Feng S, Sandhu S, Atkinson V, Tsai K, Long GV, Larkin J, Eroglu Z, Johnson DB, Sullivan R, Herkes GK, Henderson A, Carlino MS. Melanoma Res. 2022 Sep 23. doi: 10.1097/CMR.0000000000000825. Epub ahead of print. PMID: 36164923.

|

Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.

2022-11-19T22:37:15+11:00September 22nd, 2022|

Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank CU, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel JC, Ugurel S, Zimmer L, Banks P, Spain L, Soon JA, Enokida T, Tahara M, Kähler KC, Seggewiss-Bernhardt R, Harvey C, Long GV, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French LE, Knauss S, Heinzerling LM. CEur J Cancer. 2022 Sep 22;175:224-235. doi: 10.1016/j.ejca.2022.08.009. Epub ahead of print. PMID: 36155116.

 

|

Comparative genomics provides etiological and biological insights into melanoma subtypes

2022-10-09T21:35:02+11:00September 13th, 2022|

Newell F, Johansson PA, Wilmott JS, Nones K, Lakis V, Pritchard AL, Lo SN, Rawson RV, Kazakoff SH, Colebatch AJ, Koufariotis LT, Ferguson PM, Wood S, Leonard C, Law MH, Brooks KM, Broit N, Palmer JM, Couts KL, Vergara IA, Long GV, Barbour AP, Nieweg OE, Shivalingam B, Robinson WA, Stretch JR, Spillane AJ, Saw RPM, Shannon KF, Thompson JF, Mann GJ, Pearson JV, Scolyer RA, Waddell N, Hayward NK. Cancer Discov. 2022 Sep 13:CD-22-0603. doi: 10.1158/2159-8290.CD-22-0603. Epub ahead of print. PMID: 36098958.

|

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.

2022-10-23T20:07:40+11:00September 10th, 2022|

Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob J-J, Gutzner R, Jamal R, van Akkooi ACJ, Lorigan P, Grebennik D, Krepler C, Marreaud S, Suciu S, Robert C.  NEJM Evidence. 2022 Sep 10. doi: 10.1056/EVIDoa2200214. Epub ahead of print.

|

Benefit and Toxicity to PD-1 Blockade Varies by Ethnicity in Patients with Advanced Melanoma: An International Multicenter Observational Study

2025-10-20T16:28:20+11:00September 1st, 2022|

Bai X, Shoushtari AN, Betof Warner A, Si L, Tang B, Cui C, Yang X, Wei X, Quach HT, Cann CG, Zhang MZ, Pallan L, Harvey C, Kim MS, Kasumova G, Sharova T, Cohen JV, Lawrence DP, Freedman C, Fadden RM, Rubin KM, Frederick DT, Flaherty KT, Long GV, Menzies AM, Sullivan RJ, Boland GM, Johnson DB, Guo J. British Journal of Dermatology, n/a, no. n/a, (Mar 16 2022), doi:https://doi.org/10.1111/bjd.21241. TOP 10%

|

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.

2022-10-23T19:53:17+11:00September 1st, 2022|

Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Silva IP, Versluis JM, Ribero R, Angelatos AS, Tan J, Adhikari C, Menzies AM, Saw RPM, Gonzalez M, Shannon KF, Spillane AJ, Velickovic R, Lazar AJ, Damania AV, Mishra AK, Chelvanambi M, Banerjee A, Ajami NJ, Wargo JA, Macia L, Holmes AJ, Wilmott JS, Blank CU, Scolyer RA, Long GV. Nat Med 2022 Sep 22. doi: 10.1038/s41591-022-01965-2. Epub ahead of print.

|

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.

2025-05-01T09:55:56+10:00August 23rd, 2022|

Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, Thienen JVv, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H. Journal of Clinical Oncology, 0, no. 0, (Aug 23 2022): JCO.22.00343, doi:10.1200/jco.22.00343.

|

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

2025-10-30T15:22:13+11:00August 1st, 2022|

Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob J-J, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM. The Lancet, (Mar 31 2022), doi:10.1016/S0140-6736(22)00562-1. TOP 1%

|

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.

2025-05-01T09:38:58+10:00July 22nd, 2022|

Arance A, Cruz-Merino Ldl, Petrella TM, Jamal R, Ny L, Carneiro A, Berrocal A, Márquez-Rodas I, Spreafico A, Atkinson V, Svedman FC, Mant A, Khattak MA, Mihalcioiu C, Jang S, Cowey CL, Smith AD, Hawk N, Chen K, Diede SJ, Krepler C, Long GV. Journal of Clinical Oncology, 0, no. 0, (Jul 22 2022): JCO.22.00221, doi:10.1200/jco.22.00221.

|

Health-related quality of life (HRQoL) with pembrolizumab (pembro) in resected high-risk stage II melanoma in the phase 3 KEYNOTE-716 study.

2025-05-01T10:14:44+10:00June 2nd, 2022|

Khattak MA, Luke JJ, Long GV, Ascierto PA, Rutkowski P, Schadendorf D, Robert C, Grob J-J, Merino LdlC, Vecchio MD, Spagnolo F, Mackiewicz J, -Sileni VC, Carlino MS, Mohr P, Jiang R, Fukunaga-Kalabis M, Krepler C, Eggermont AM, Kirkwood JM. Journal of Clinical Oncology, 40, no. 16_suppl, (Jun 02 2022): 9581-81, doi:10.1200/JCO.2022.40.16_suppl.9581.

|

Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma

2025-08-20T16:51:49+10:00April 1st, 2022|

Irene L M Reijers, Robert V Rawson, Andrew J Colebatch, Elisa A Rozeman, Alex M Menzies, Alexander C J van Akkooi, Kerwin F Shannon, Michel W Wouters, Robyn P M Saw, Winan J van Houdt, Charlotte L Zuur, Omgo E Nieweg, Sydney Ch’ng, W Martin C Klop, Andrew J Spillane, Georgina V Long, Richard A Scolyer, Bart A van de Wiel, Christian U Blank. JAMA Surg. 157(4):335–342. doi:10.1001/jamasurg.2021.7554

|

Anatomic position determines oncogenic specificity in melanoma.

2025-07-24T12:09:45+10:00March 30th, 2022|

Weiss JM, Hunter MV, Cruz NM, Baggiolini A, Tagore M, Ma Y, Misale S, Marasco M, Simon-Vermot T, Campbell NR, Newell F, Wilmott JS, Johannson PA, Thompson JF, Long GV, Pearson JV, Mann GJ, Scolyer RA, Waddell N, Montal ED, Huang T-H, Jonnson P, Donoghue MTA, Harris CC, Taylor BS, Xu T, Chaligne R, Shliaha PV, Hendrickson R, Jungbluth AA, Lezcano C, Koche R, Studer L, Ariyan CE, Solit DB, Wolchok JD, Merghoub T, Rosen N, Hayward NK, White RM. Nature, (March 30 2022).

|

Anatomic position determines oncogenic specificity in melanoma

2025-11-10T14:23:23+11:00March 22nd, 2022|

Weiss JM, Hunter MV, Cruz NM, Baggiolini A, Tagore M, Ma Y, Misale S, Marasco M, Simon-Vermot T, Campbell NR, Newell F, Wilmott JS, Johansson PA, Thompson JF, Long GV, Pearson JV, Mann GJ, Scolyer RA, Waddell N, Montal ED, Huang T-H, Jonsson P, Donoghue MTA, Harris CC, Taylor BS, Xu T, Chaligné R, Shliaha PV, Hendrickson R, Jungbluth AA, Lezcano C, Koche R, Studer L, Ariyan CE, Solit DB, Wolchok JD, Merghoub T, Rosen N, Hayward NK, White RM. Nature, 604, no. 7905, (Apr 01 2022): 354-61, doi:10.1038/s41586-022-04584-6. TOP 1%

|

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

2025-10-30T14:07:15+11:00February 24th, 2022|

Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. Eur J Cancer, 165(Feb 24 2022): 97-112, doi:10.1016/j.ejca.2022.01.017.

|

Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

2025-11-05T16:13:27+11:00February 10th, 2022|

Silva IPd, Ahmed T, McQuade JL, Nebhan CA, Park JJ, Versluis JM, Serra-Bellver P, Khan Y, Slattery T, Oberoi HK, Ugurel S, Haydu LE, Herbst R, Utikal J, Pföhler C, Terheyden P, Weichenthal M, Gutzmer R, Mohr P, Rai R, Smith JL, Scolyer RA, Arance AM, Pickering L, Larkin J, Lorigan P, Blank CU, Schadendorf D, Davies MA, Carlino MS, Johnson DB, Long GV, Lo SN, Menzies AM. Journal of Clinical Oncology, 0, no. 0, (Feb 10 2022): JCO.21.01701, doi:10.1200/jco.21.01701. TOP 10%

|

Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.

2025-07-24T11:52:41+10:00February 10th, 2022|

Pires da Silva I, Ahmed T, McQuade JL, Nebhan C, Park JJ, Versluis J, Serra-Bellver P, Khan Y, Slattery T, Oberoi H, Ugurel S, Haydu LE, Herbst R, Utikal J, Pfoehler C, Terheyden P, Weichenthal M, Gutzmer R, Mohr P, Rai R, Smith JL, Scolyer RA, Arance A, Pickering L, Larkin J, Lorigan P, Blank CU, Schadendorf D, Davies MA, Carlino MS, Johnson DB, Long GV, Lo SN, Menzies AM. Journal of Clinical Oncology, (Jan 23 (accepted) 2022).

|

Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma

2025-11-05T15:50:38+11:00February 9th, 2022|

Reijers ILM, Rawson RV, Colebatch AJ, Rozeman EA, Menzies AM, van Akkooi ACJ, Shannon KF, Wouters MW, Saw RPM, van Houdt WJ, Zuur CL, Nieweg OE, Ch’ng S, Klop WMC, Spillane AJ, Long GV, Scolyer RA, van de Wiel BA, Blank CU. JAMA Surgery, (Feb 9 2022), doi:10.1001/jamasurg.2021.7554. TOP 1%

|

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

2025-11-10T14:02:39+11:00January 28th, 2022|

van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Olofsson Bagge R, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI, International Neoadjuvant Melanoma C. Annals of Surgical Oncology, (Jan 28 2022), doi:10.1245/s10434-021-11236-y. TOP 10%

|

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).

2025-07-24T12:06:17+10:00January 28th, 2022|

van Akkooi ACJ, Kieken TJ, Burton eM, Ariyan c, Ascierto P, Asero s, Blank C, Block MS, Boland G, Caraco C, Davidson S, Duprat J, Faries M, Gershenwald J, Grunhagen D, Gyorki dE, Han D, Hayes A, van Houdt WJ, Karakousis g, Klop M, Long G, Lowe MC, Menzies A, Olofsson R, Ross MI, Rutkowski P, Saw RPM, Scolyer r, Sondak v, Spillane AJ, Tawbi H, Testori AAE, Thompson J, Zager J, Zuur CL, Wargo JA. Annals of Surgical Oncology., (Jan 28 2022).

|

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma

2025-10-27T17:04:51+11:00January 14th, 2022|

Dummer R, Long GV, Robert C, Tawbi HA, Flaherty KT, Ascierto PA, Nathan PD, Rutkowski P, Leonov O, Dutriaux C, Mandalà M, Lorigan P, Ferrucci PF, Grob JJ, Meyer N, Gogas H, Stroyakovskiy D, Arance A, Brase JC, Green S, Haas T, Masood A, Gasal E, Ribas A, Schadendorf D. J Clin Oncol, (Jan 14 2022): Jco2101601, doi:10.1200/jco.21.01601. TOP 10%

|

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.

2025-07-24T12:37:35+10:00January 12th, 2022|

Dummer R, Long GV, Robert C, Tawbi HA, Flaherty KT, Ascierto PA, Nathan PD, Rutkowski P, Leonov O, Dutriaux C, Mandalà M, Lorigan P, Ferrucci PF, Grob JJ, Meyer N, Gogas H, Stroyakovskiy D, Arance A, Brase JC, Green S, Haas T, Masood A, Gasal E, Ribas A, Schadendorf D. J Clin Oncol, (Jan 14 2022): Jco2101601, doi:10.1200/jco.21.01601.

|

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance

2025-11-05T15:16:06+11:00January 10th, 2022|

Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, Blank CU, Thompson JF, Spillane AJ, Saw RPM, Shannon KF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA, Waddell N, Long GV. Cancer Cell, 40, no. 1, (Jan 10 2022): 88-102.e7, doi:10.1016/j.ccell.2021.11.012. TOP 10%

|

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

2025-11-05T16:36:07+11:00January 6th, 2022|

Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV. N Engl J Med, 386, no. 1, (Jan 6 2022): 24-34, doi:10.1056/NEJMoa2109970. TOP 1%

|

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

2025-07-24T13:27:54+10:00January 6th, 2022|

Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV. N Engl J Med 386, no. 1 (Jan 6 2022): 24-34, doi:10.1056/NEJMoa2109970.

|

BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

2025-11-05T16:05:34+11:00December 21st, 2021|

Scolyer RA, Atkinson V, Gyorki DE, Lambie D, O’Toole S, Saw RPM, Amanuel B, Angel CM, Button-Sloan AE, Carlino MS, Ch’ng S, Colebatch AJ, Daneshvar D, Pires da Silva I, Dawson T, Ferguson PM, Foster-Smith E, Fox SB, Gill AJ, Gupta R, Henderson MA, Hong AM, Howle JR, Jackett LA, James C, Lee CS, Lochhead A, Loh D, McArthur GA, McLean CA, Menzies AM, Nieweg OE, O’Brien BH, Pennington TE, Potter AJ, Prakash S, Rawson RV, Read RL, Rtshiladze MA, Shannon KF, Smithers BM, Spillane AJ, Stretch JR, Thompson JF, Tucker P, Varey AHR, Vilain RE, Wood BA, Long GV. Pathology, 54, no. 1, (Feb 2022): 6-19, doi:10.1016/j.pathol.2021.11.002.

|

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis

2025-10-30T13:26:31+11:00December 21st, 2021|

Goldinger SM, Buder-Bakhaya K, Lo SN, Forschner A, McKean M, Zimmer L, Khoo C, Dummer R, Eroglu Z, Buchbinder EI, Ascierto PA, Gutzmer R, Rozeman EA, Hoeller C, Johnson DB, Gesierich A, Kölblinger P, Bennannoune N, Cohen JV, Kähler KC, Wilson MA, Cebon J, Atkinson V, Smith JL, Michielin O, Long GV, Hassel JC, Weide B, Haydu LE, Schadendorf D, McArthur G, Ott PA, Blank C, Robert C, Sullivan R, Hauschild A, Carlino MS, Garbe C, Davies MA, Menzies AM. Eur J Cancer, 162(Feb 2022): 22-33, doi:10.1016/j.ejca.2021.11.022.

|

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.

2025-07-24T13:09:58+10:00December 21st, 2021|

Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, Blank CU, Thompson JF, Spillane AJ, Saw RPM, Shannon KF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA, Waddell N, Long GV. Cancer Cell, (Dec 21 2021), doi:10.1016/j.ccell.2021.11.012.

|

BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.

2025-07-24T13:23:31+10:00December 19th, 2021|

Scolyer RA, Atkinson V, Gyorki DE, Lambie D, O’Toole S, Saw RPM, Amanuel B, Angel CM, Button-Sloan AE, Carlino MS, Ch’ng S, Colebatch AJ, Daneshvar D, Pires da Silva I, Dawson T, Ferguson PM, Foster-Smith E, Fox SB, Gill AJ, Gupta R, Henderson MA, Hong AM, Howle JR, Jackett LA, James C, Lee CS, Lochhead A, Loh D, McArthur GA, McLean CA, Menzies AM, Nieweg OE, O’Brien BH, Pennington TE, Potter AJ, Prakash S, Rawson RV, Read RL, Rtshiladze MA, Shannon KF, Smithers BM, Spillane AJ, Stretch JR, Thompson JF, Tucker P, Varey AHR, Vilain RE, Wood BA, Long GV. Pathology, (Dec 19 2021), doi:10.1016/j.pathol.2021.11.002.

|

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.

2022-07-23T17:15:22+10:00November 24th, 2021|

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. J Clin Oncol. (Epub 24 Nov 2021)

|

Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis.

2022-07-23T16:44:16+10:00October 21st, 2021|

Zaremba A, Kramer R, De Temple V, Bertram S, Salzmann M, Gesierich A, Reinhardt L, Baroudjian B, Sachse MM, Mechtersheimer G, Johnson DB, Weppler AM, Spain L, Loquai C, Dudda M, Pföhler C, Hepner A, Long GV, Menzies AM, Carlino MS, Lebbé C, Enokida T, Tahara M, Bröckelmann PJ, Eigentler T, Kähler KC, Gutzmer R, Berking C, Ugurel S, Stadtler N, Sucker A, Becker JC, Livingstone E, Meier F, Hassel JC, Schadendorf D, Hanoun M, Heinzerling L, Zimmer L. Front Oncol. (21 Oct 2021)

|

Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy

2022-07-23T18:42:02+10:00August 10th, 2021|

Bai X, Hu J, Betof Warner A, Quach HT, Cann CG, Zhang MZ, Si L, Tang B, Cui C, Yang X, Wei X, Pallan L, Harvey C, Manos MP, Ouyang O, Kim MS, Kasumova G, Cohen JV, Lawrence DP, Freedman C, Fadden RM, Rubin KM, Sharova T, Frederick DT, Flaherty KT, Rahma OE, Long GV, Menzies AM, Guo J, Shoushtari AN, Johnson DB, Sullivan RJ, Boland GM. Clin Cancer Res. (Epub 10 Aug 2021)

|

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

2022-07-23T22:00:01+10:00June 9th, 2021|

Brase JC, Walter RFH, Savchenko A, Gusenleitner D, Garrett J, Schimming TT, Váraljai R, Castelletti D, Kim JY, Dakappagari NK, Schultz K, Robert C, Long GV, Nathan PD, Ribas A, Flaherty KT, Karaszewska B, Schachter J, Sucker A, Schmid KW, Zimmer L, Livingstone E, Gasal E, Schadendorf D, Roesch A. Clin Cancer Res. (Epub 9 June 2021)

|

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

2025-05-29T11:47:45+10:00May 11th, 2021|

Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, Zimmer L, Trojaniello C, Stout D, Lyle M, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Blank CU, Menzies AM, Long GV. Lancet Oncol. (Epub 11 May 2021)

|

The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.

2025-05-29T12:10:23+10:00May 7th, 2021|

Versluis JM, Hendriks AM, Weppler AM, Brown LJ, de Joode K, Suijkerbuijk KPM, Zimmer L, Kapiteijn EW, Allayous C, Johnson DB, Hepner A, Mangana J, Bhave P, Jansen YJL, Trojaniello C, Atkinson V, Storey L, Lorigan P, Ascierto PA, Neyns B, Haydon A, Menzies AM, Long GV, Lebbe C, van der Veldt AAM, Carlino MS, Sandhu S, van Tinteren H, de Vries EGE, Blank CU, Jalving M. Eur J Cancer. 2021 May 7;151:72-83.

|

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

2025-05-29T12:17:10+10:00May 1st, 2021|

Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Eggermont AMM; EORTC Melanoma Group. Lancet Oncol. 2021 May;22(5):655-664.

|

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

2022-07-25T21:12:03+10:00April 30th, 2021|

Jason J Luke, Prof Piotr Rutkowski, Paola Queirolo, Michele Del Vecchio, Prof Jacek Mackiewicz, Vanna Chiarion-Sileni, Luis de la Cruz Merino, Prof Muhammad A Khattak, Prof Dirk Schadendorf, Prof Georgina V Long, Paolo A Ascierto, Mario Mandala, Federica De Galitiis, Andrew Haydon, Reinhard Dummer, Prof Jean-Jacques Grob, Caroline Robert, Matteo S Carlino, Peter Mohr, Andrew Poklepovic, Prof Vernon K Sondak, Prof Richard A Scolyer, John M Kirkwood, Ke Chen, Scott J Diede, Sama Ahsan, Nageatte Ibrahim, Prof Alexander M M. Lancet. (30 Apr 2022)

|

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

2025-08-21T16:33:36+10:00April 12th, 2021|

Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob J-J, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Menzies A, Lesimple T, Maio M, Linette G, Brown M, Hersey P, Svane IM, Mortier L, Schachter J, Barrow C, Kudchadkar R, Song X, Dutriaux C, Quaglino P, Meier F, Queirolo P, Stroyakovskiy D, Bastholt L, Guillot B, Garbe C, Ortiz Romero PL, Grange F, Mohr P, Algazi A, Bechter O, Hernberg M, Arnault J-P, Saiag P, Loquai C, Meiss F, Simon J-C, Bar-Sela G, Chiarion Sileni V, Fitzharris B, McCrystal M, Parente P, Baurain J-F, Combemale P, Lebbe C, Hauschild A, Yamazaki N, Dummer R, Milhem M, Dzienis M, Walker J, Geoffrois L, Leccia M-T, Kretschmer L, Hendler D, Lotem M, Mackiewicz A, Sekulovic L, Dunwoodie E, Hoeller C, Machet L, Hassel J, Hospers GAP, Passos M-J, Levin M, Fehr M, Corrie P, Waterston A, Hallmeyer S, Schmidt H, Descamps V, Lacour J-P, Berking C, Kiecker F, Ferrucci PF, Yokota K, Aarts M, Jameson M, Winge-Main AK, Ferreira P, Kim K, McNeil C, Hofmann-Wellenhof R, Kerger J, Aubin F, Utikal J, Ferraresi V, Inozume T, Kiyohara Y, Groenewegen G, Kapiteijn H, Matkovic S, Boehncke W-H, Casasola R, Crook T, Marshall E, Skytta T, Avril M-F, Jouary T, Hein R, Terheyden P, Aoi J, Takenouchi T, Straume O, Martins C, Mukhametshina G, Nathan P. The Lancet Oncology, doi:https://doi.org/10.1016/S1470-2045(21)00065-6. TOP 10%

|

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.

2025-05-29T12:36:22+10:00March 30th, 2021|

Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, Martínez-Vila C, Wallace R, Bhave P, Reijers I, Thompson N, Vanella V, Gerard C, Aspeslagh S, Labianca A, Khattak A, Mandala M, Xu W, Neyns B, Michielin O, Blank CU, Welsh SJ, Haydon A, Sandhu S, Mangana J, McQuade JL, Ascierto PA, Zimmer L, Johnson DB, Arance A, Lorigan P, Lebbé C, Carlino MS, Sullivan R, Long GV, Menzies AM. Ann Oncol. 2021 Mar 30:S0923-7534(21)01101-7.

|

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.

2025-05-29T15:41:09+10:00March 17th, 2021|

Rawson RV, Adhikari C, Bierman C, Lo S, Shklovskaya E, Rozeman EA, Menzies AM, van Akkooi ACJ, Shannon KF, Gonzalez M M, Guminski AD, Tetzlaff MT, Stretch JR, Eriksson H, van Thienen JV, Wouters MW, Haanen JBAG, Klop WMC, Zuur CL, van Houdt WJ, Nieweg OE, Ch’ng S, Rizos H, Saw RPM, Spillane AJ, Wilmott JS, Blank CU, Long GV, van de Wiel BA, Scolyer RA. Ann Oncol. (Epub 17 March 2021)

|

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.

2025-05-29T15:59:17+10:00March 15th, 2021|

Knispel S, Gassenmaier M, Menzies AM, Loquai C, Johnson DB, Franklin C, Gutzmer R, Hassel JC, Weishaupt C, Eigentler T, Schilling B, Schummer P, Sirokay J, Kiecker F, Owen CN, Fleischer MI, Cann C, Kähler KC, Mohr P, Bluhm L, Niebel D, Thoms KM, Goldinger SM, Reinhardt L, Meier F, Berking C, Reinhard R, Susok L, Ascierto PA, Drexler K, Pföhler C, Tietze J, Heinzerling L, Livingstone E, Ugurel S, Long GV, Stang A, Schadendorf D, Zimmer L. Eur J Cancer. (Epub 15 March 2021)

|

Tumour gene expression signature in primary melanoma predicts long-term outcomes.

2025-06-26T11:24:33+10:00February 18th, 2021|

Garg M, Couturier DL, Nsengimana J, Fonseca NA, Wongchenko M, Yan Y, Lauss M, Jönsson GB, Newton-Bishop J, Parkinson C, Middleton MR, Bishop DT, McDonald S, Stefanos N, Tadross J, Vergara IA, Lo S, Newell F, Wilmott JS, Thompson JF, Long GV, Scolyer RA, Corrie P, Adams DJ, Brazma A, Rabbie R. Nat Commun. 2021 Feb 18;12(1):1137

|

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

2022-06-09T10:58:09+10:00February 9th, 2021|

Alexander M. Menzies, Rodabe N. Amaria, Elisa A. Rozeman, Alexander C. Huang, Michael T. Tetzlaff, Bart A. van de Wiel, Serigne Lo, Ahmad A. Tarhini, Elizabeth M. Burton, Thomas E. Pennington, Robyn P. M. Saw, Xiaowei Xu, Giorgos C. Karakousis, Paolo A. Ascierto, Andrew J. Spillane, Alexander C. J. van Akkooi, Michael A. Davies, Tara C. Mitchell, Hussein A. Tawbi, Richard A. Scolyer, Jennifer A. Wargo, Christian U. Blank & Georgina V. Long.  Nat Med (2021).

|

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.

2025-06-23T15:35:09+10:00February 8th, 2021|

Rozeman EA, Hoefsmit EP, Reijers ILM, Saw RPM, Versluis JM, Krijgsman O, Dimitriadis P, Sikorska K, van de Wiel BA, Eriksson H, Gonzalez M, Torres Acosta A, Grijpink-Ongering LG, Shannon K, Haanen JBAG, Stretch J, Ch’ng S, Nieweg OE, Mallo HA, Adriaansz S, Kerkhoven RM, Cornelissen S, Broeks A, Klop WMC, Zuur CL, van Houdt WJ, Peeper DS, Spillane AJ, van Akkooi ACJ, Scolyer RA, Schumacher TNM, Menzies AM, Long GV, Blank CU. Nat Med. (Epub Feb 8 2021)

|

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.

2022-07-25T22:17:12+10:00February 1st, 2021|

Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, Sullivan RJ, Chiarion-Sileni V, Nyakas M, Kahler K, Hauschild A, Plummer R, Trojaniello C, Ascierto PA, Zimmer L, Schadendorf D, Allayous C, Lebbe C, Maurichi A, Santinami M, Roy S, Robert C, Lesimple T, Patel S, Versluis JM, Blank CU, Khattak A, Van der Westhuizen A, Carlino MS, Shackleton M, Haydon A. Br J Cancer. 2021 Feb;124(3):574-580.

|

Go to Top